Wells Fargo & Company Adverum Biotechnologies, Inc. Transaction History

Wells Fargo & Company

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$0.75 - $1.26 $723 - $1,215	-965 Reduced 49.72%	976 $0
Q3 2023 Nov 13, 2023	BUY	$1.5 - $2.33 $1,900 - $2,952	1,267 Added 187.98%	1,941 $2,000
Q2 2023 Aug 15, 2023	BUY	$0.68 - $1.59 $22 - $52	33 Added 5.15%	674 $1,000
Q1 2023 May 12, 2023	BUY	$0.62 - $0.85 $5 - $7	9 Added 1.42%	641 $0
Q4 2022 Feb 13, 2023	BUY	$0.54 - $10.3 $11 - $226	22 Added 3.61%	632 $0
Q3 2022 Nov 14, 2022	SELL	$0.96 - $9.68 $137 - $1,384	-143 Reduced 18.99%	610 $1,000
Q2 2022 Aug 12, 2022	SELL	$0.81 - $1.34 $6,675 - $11,042	-8,241 Reduced 91.63%	753 $1,000
Q1 2022 May 16, 2022	SELL	$1.23 - $1.95 $37,351 - $59,215	-30,367 Reduced 77.15%	8,994 $11,000
Q4 2021 Feb 14, 2022	BUY	$1.74 - $2.4 $68,392 - $94,334	39,306 Added 71465.45%	39,361 $69,000
Q3 2021 Nov 15, 2021	SELL	$2.08 - $3.6 $520 - $900	-250 Reduced 81.97%	55 $0
Q2 2021 Aug 16, 2021	SELL	$3.36 - $10.56 $41,741 - $131,186	-12,423 Reduced 97.6%	305 $1,000
Q1 2021 May 13, 2021	SELL	$9.26 - $14.36 $605,798 - $939,445	-65,421 Reduced 83.71%	12,728 $126,000
Q4 2020 Feb 09, 2021	BUY	$9.84 - $14.26 $324,070 - $469,638	32,934 Added 72.84%	78,149 $848,000
Q3 2020 Nov 05, 2020	SELL	$10.3 - $21.64 $37,543 - $78,877	-3,645 Reduced 7.46%	45,215 $467,000
Q2 2020 Aug 13, 2020	BUY	$8.53 - $25.64 $117,816 - $354,139	13,812 Added 39.41%	48,860 $1.02 Million
Q1 2020 May 14, 2020	BUY	$7.98 - $16.32 $279,683 - $571,983	35,048 New	35,048 $343,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.